These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 24520903)

  • 21. Optimizing the hit-to-lead process using SPR analysis.
    Löfås S
    Assay Drug Dev Technol; 2004 Aug; 2(4):407-15. PubMed ID: 15357922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of weak affinity chromatography and surface plasmon resonance in determining affinity of small molecules.
    Duong-Thi MD; Bergström G; Mandenius CF; Bergström M; Fex T; Ohlson S
    Anal Biochem; 2014 Sep; 461():57-9. PubMed ID: 24915639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A combinatorial biophysical approach; FTSA and SPR for identifying small molecule ligands and PAINs.
    Redhead M; Satchell R; Morkūnaitė V; Swift D; Petrauskas V; Golding E; Onions S; Matulis D; Unitt J
    Anal Biochem; 2015 Jun; 479():63-73. PubMed ID: 25837771
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fragment-based activity space: smaller is better.
    Hesterkamp T; Whittaker M
    Curr Opin Chem Biol; 2008 Jun; 12(3):260-8. PubMed ID: 18316043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biodiversity of small molecules--a new perspective in screening set selection.
    Petrone PM; Wassermann AM; Lounkine E; Kutchukian P; Simms B; Jenkins J; Selzer P; Glick M
    Drug Discov Today; 2013 Jul; 18(13-14):674-80. PubMed ID: 23454345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design of screening collections for successful fragment-based lead discovery.
    Na J; Hu Q
    Methods Mol Biol; 2011; 685():219-40. PubMed ID: 20981526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug-likeness and increased hydrophobicity of commercially available compound libraries for drug screening.
    Zuegg J; Cooper MA
    Curr Top Med Chem; 2012; 12(14):1500-13. PubMed ID: 22827520
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systematic screening of viral entry inhibitors using surface plasmon resonance.
    Kumar PKR
    Rev Med Virol; 2017 Nov; 27(6):. PubMed ID: 29047180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biophysical methods for identifying fragment-based inhibitors of protein-protein interactions.
    Pfaff SJ; Chimenti MS; Kelly MJ; Arkin MR
    Methods Mol Biol; 2015; 1278():587-613. PubMed ID: 25859978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SPR-based fragment screening: advantages and applications.
    Neumann T; Junker HD; Schmidt K; Sekul R
    Curr Top Med Chem; 2007; 7(16):1630-42. PubMed ID: 17979772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fragment-based discovery of focal adhesion kinase inhibitors.
    Grädler U; Bomke J; Musil D; Dresing V; Lehmann M; Hölzemann G; Greiner H; Esdar C; Krier M; Heinrich T
    Bioorg Med Chem Lett; 2013 Oct; 23(19):5401-9. PubMed ID: 23973211
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-throughput fragment screening by affinity LC-MS.
    Duong-Thi MD; Bergström M; Fex T; Isaksson R; Ohlson S
    J Biomol Screen; 2013 Feb; 18(2):160-71. PubMed ID: 22983162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integration of fragment screening and library design.
    Siegal G; Ab E; Schultz J
    Drug Discov Today; 2007 Dec; 12(23-24):1032-9. PubMed ID: 18061882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Algorithms for the automated selection of fragment-like molecules using single-point surface plasmon resonance measurements.
    Kreatsoulas C; Narayan K
    Anal Biochem; 2010 Jul; 402(2):179-84. PubMed ID: 20371355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Applied Biophysical Methods in Fragment-Based Drug Discovery.
    Coyle J; Walser R
    SLAS Discov; 2020 Jun; 25(5):471-490. PubMed ID: 32345095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Affinity-based screening techniques: their impact and benefit to increase the number of high quality leads.
    Bergsdorf C; Ottl J
    Expert Opin Drug Discov; 2010 Nov; 5(11):1095-107. PubMed ID: 22827747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methods for docking small molecules to macromolecules: a user's perspective. 2. Applications.
    Campagna-Slater V; Therrien E; Weill N; Moitessier N
    Curr Pharm Des; 2014; 20(20):3360-72. PubMed ID: 23947644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Parallel chemistry in the 21st century.
    Long A
    Curr Protoc Pharmacol; 2012 Sep; Chapter 9():Unit9.16. PubMed ID: 22948852
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fragment-based screening using surface plasmon resonance technology.
    Perspicace S; Banner D; Benz J; Müller F; Schlatter D; Huber W
    J Biomol Screen; 2009 Apr; 14(4):337-49. PubMed ID: 19403917
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging role of surface plasmon resonance in fragment-based drug discovery.
    Navratilova I; Hopkins AL
    Future Med Chem; 2011 Oct; 3(14):1809-20. PubMed ID: 22004086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.